ResearcherUniversity of Florida HealthActive in the last 2 years
Jesus C. Fabregas
Matched on ORCID iD 0000-0003-1120-1783; OpenAlex author ID A5015653794. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 2 papers
Papers 5
- Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial. Co-author DOI 10.1093/oncolo/oyag250↗
- Neoadjuvant Therapy for Localized Pancreatic Cancer. Co-author DOI 10.3390/cancers18061011↗
- National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.06.018↗
- A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. Co-author DOI 10.2217/fon-2023-0256↗
- Association of social determinants of health with late diagnosis and survival of patients with pancreatic cancer. Co-author DOI 10.21037/jgo-21-788↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Thomas J. George · 5 shared papers, 2022–2026 · strength 1.01
- Paper Neoadjuvant Therapy for Localized Pancreatic Cancer. DOI 10.3390/cancers18061011↗
- Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
- Paper Association of social determinants of health with late diagnosis and survival of patients with pancreatic cancer. DOI 10.21037/jgo-21-788↗
- Ibrahim Nassour · 4 shared papers, 2023–2026 · strength 0.82
- Paper Neoadjuvant Therapy for Localized Pancreatic Cancer. DOI 10.3390/cancers18061011↗
- Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
- Paper National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. DOI 10.1016/j.hpb.2023.06.018↗
- Kathryn E. Hitchcock · 4 shared papers, 2023–2026 · strength 0.82
- Paper Neoadjuvant Therapy for Localized Pancreatic Cancer. DOI 10.3390/cancers18061011↗
- Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
- Paper National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. DOI 10.1016/j.hpb.2023.06.018↗
- Steven J. Hughes · 4 shared papers, 2023–2026 · strength 0.82
- Paper Neoadjuvant Therapy for Localized Pancreatic Cancer. DOI 10.3390/cancers18061011↗
- Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
- Paper National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. DOI 10.1016/j.hpb.2023.06.018↗
- Sherise Chantell Rogers · 3 shared papers, 2023–2026 · strength 0.56
- Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
- Paper National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. DOI 10.1016/j.hpb.2023.06.018↗
- Paper A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. DOI 10.2217/fon-2023-0256↗
- Alessandro Paniccia · 2 shared papers, 2023–2026 · strength 0.43
- Ryan Michael Thomas · 2 shared papers, 2023–2026 · strength 0.39
- Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
- Paper A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. DOI 10.2217/fon-2023-0256↗
- Omar Roger Kayaleh · 2 shared papers, 2023–2026 · strength 0.39
- Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
- Paper A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. DOI 10.2217/fon-2023-0256↗
- Aleksey A. Novikov · 1 shared paper, 2026 · strength 0.26
- Abdul Qahar Khan Yasinzai · 1 shared paper, 2026 · strength 0.26
- Patrick W. Underwood · 1 shared paper, 2026 · strength 0.26
- Jordan A. McKean · 1 shared paper, 2026 · strength 0.26
- Bashar J. Qumseya · 1 shared paper, 2026 · strength 0.26
- Z. Hugh Fan · 1 shared paper, 2026 · strength 0.24
- Miranda B. Lam · 1 shared paper, 2022 · strength 0.19
- Ruchi Singhal · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.